Menu

GLP-1 medicines guide · 3 min read

Semaglutide targets one gut hormone receptor. Tirzepatide targets two.

The short answer

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors. In a head-to-head trial of the branded products, tirzepatide led to more weight loss on average. Both commonly cause stomach and bowel side effects and share key warnings. Neither is best for everyone. A licensed clinician weighs your history, goals, tolerance and cost.

Livozo expects to offer clinician-reviewed access to semaglutide and tirzepatide through a licensed clinical partner. Care is not live today. This guide does not recommend a specific medication.

How the two medicines work

Semaglutide is a GLP-1 receptor agonist. It acts like a gut hormone that helps control appetite and blood sugar. Wegovy is the FDA-approved semaglutide brand for weight management.[1]

Tirzepatide activates two hormone receptors: GIP and GLP-1. Zepbound is the FDA-approved tirzepatide brand for weight management. The branded injectable forms of both medicines are given once a week under the skin.[2]

Each medicine also has a brand for type 2 diabetes: Ozempic for semaglutide and Mounjaro for tirzepatide.

Compounded semaglutide and compounded tirzepatide are different from these brands. They are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold. They are not generic versions of any brand.[3]

What the trials found, and their limits

In the STEP 1 trial, adults without diabetes used branded semaglutide with lifestyle support for 68 weeks. Average weight change was about 15% with semaglutide and about 2% with placebo. Results varied from person to person.[4]

In the SURMOUNT-1 trial, adults without diabetes used branded tirzepatide for 72 weeks. Average weight change ranged from 15% to 21% depending on dose, compared with about 3% on placebo.[5]

SURMOUNT-5 compared the two branded medicines directly in 751 adults with obesity and without type 2 diabetes. After 72 weeks, average weight change was about 20% with tirzepatide and about 14% with semaglutide. The trial was open-label, so participants knew which medicine they took, and the maker of tirzepatide funded it.[6]

All three trials studied the FDA-approved branded products, not compounded versions. They report group averages. They cannot tell you how your own body will respond.

Side effects and warnings they share

In the trials, the most common side effects of both medicines were digestive, such as nausea, diarrhea, vomiting and constipation. Most were mild to moderate and happened while the dose was being increased.[4][5][6]

Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Neither medicine should be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both labels also warn about pancreatitis, gallbladder disease, kidney injury from dehydration, serious allergic reactions and risks during anesthesia.[1][2]

How a clinician might choose

There is no single best choice. A licensed clinician looks at your medical history, your other medicines, how you have tolerated similar drugs, your goals and what is available and affordable.

Some details point one way or the other. For example, the tirzepatide label advises people who use oral birth control pills to add or switch to another method for a period after starting and after each dose increase. A clinician should explain details like this before any decision.[2]

Questions to ask a clinician

Why do you suggest this medicine for me and not the other one? Is it a branded product or a compounded preparation, and why? How will we handle side effects while the dose goes up?

What follow-up will we have, and how do I reach you between visits? Which symptoms mean I should stop and seek urgent care?

What we know

  • Semaglutide acts on one hormone receptor (GLP-1). Tirzepatide acts on two (GIP and GLP-1).
  • Large trials of the branded products showed meaningful average weight loss compared with placebo.
  • In one open-label head-to-head trial of the branded products, tirzepatide produced more average weight loss than semaglutide.
  • Digestive side effects are the most common for both medicines.

What we don't know yet

  • How compounded versions perform. The major trials studied branded products only.
  • Which medicine will suit a specific person before they try it.
  • Long-term and rare safety outcomes beyond the length of current trials.

Safety

  • Do not use either medicine with a personal or family history of medullary thyroid carcinoma or MEN 2.
  • Seek urgent care for severe stomach pain that does not go away, signs of a serious allergic reaction, or signs of severe dehydration.
  • Tell every clinician and your anesthesia team that you take a GLP-1 medicine before any surgery or procedure.

This guide is education, not medical advice. It does not create a clinician-patient relationship. If you think you are having an emergency, call 911.

Sources

  1. DailyMed (NLM) — Wegovy (semaglutide) prescribing information
  2. DailyMed (NLM) — Zepbound (tirzepatide) prescribing information
  3. FDA — Human drug compounding
  4. Wilding et al. — Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021
  5. Jastreboff et al. — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022
  6. Aronne et al. — Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med, 2025

Keep reading.